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Hepatitis C virus (HCV) leads to progressive liver disease and hepatocellular carcinoma. Current treatments are only par-
tially effective, and new therapies targeting viral and host pathways are required. Virus entry into a host cell provides a
conserved target for therapeutic intervention. Tetraspanin CD81, scavenger receptor class B member I, and the tight-junc-
tion proteins claudin-1 and occludin have been identified as essential entry receptors. Limited information is available on
the role of receptor trafficking in HCV entry. We demonstrate here that anti-CD81 antibodies inhibit HCV infection at late
times after virus internalization, suggesting a role for intracellular CD81 in HCV infection. Several tetraspanins have been
reported to internalize via motifs in their C-terminal cytoplasmic domains; however, CD81 lacks such motifs, leading sev-
eral laboratories to suggest a limited role for CD81 endocytosis in HCV entry. We demonstrate CD81 internalization via a
clathrin- and dynamin-dependent process, independent of its cytoplasmic domain, suggesting a role for associated partner
proteins in regulating CD81 trafficking. Live cell imaging demonstrates CD81 and claudin-1 coendocytosis and fusion with
Rab5 expressing endosomes, supporting a role for this receptor complex in HCV internalization. Receptor-specific anti-
bodies and HCV particles increase CD81 and claudin-1 endocytosis, supporting a model wherein HCV stimulates receptor
trafficking to promote particle internalization.
Hepatitis C virus (HCV) is a member of the Flaviviridae familyand an important human pathogen that leads to progressive
liver disease and is a leading indication for liver transplantation.
At present, there is no HCV vaccine, and the only approved ther-
apy, interferon and ribavirin, has limited efficacy. Unsurprisingly,
there is an international effort to develop new antiviral agents and
vaccines that are effective across all major HCV genotypes. A
number of drugs targetingHCV replicase enzymes are in develop-
ment; however, recent trials show a rapid appearance of drug-
resistant viruses (for reviews, see references 1 and 52). The essen-
tial and conserved nature of the entry step in the HCV life cycle
offers an attractive target for therapeutic intervention.
Virus entry into a host cell is defined by specific interaction(s)
with cell surface proteins or receptors that confer host and cellular
tropism (66). Recent advances in the development of in vitro sys-
tems to study the HCV life cycle have demonstrated an essential
role for tetraspanin CD81 (54), scavenger receptor BI (SR-BI)
(58), and tight-junction protein occludin (3, 42, 55) and several
members of the claudin family (21, 47, 76) in virus entry. Low-
density lipoprotein receptor and cell surface glycosaminoglycans,
including heparan sulfate, have been reported to play a role in the
initial attachment of HCV to the cell surface (2, 49). Coexpression
of human CD81, SR-BI, occludin, and claudin-1 renders nonliver
cells permissive for HCV entry, demonstrating that these four
proteins constitute the minimal viral receptor requirement (18,
55). CD81 and SR-BI bindHCV encoded E1E2 glycoproteins with
high affinity (54, 58), and antibodies targeting these molecules
neutralize virus infection after cell attachment, suggesting a role
for CD81 and SR-BI in the lateral diffusion and endocytosis of
HCVparticles (12). In contrast, there is limited evidence for tight-
junction protein association with HCV, which may reflect an in-
direct role for these proteins in the virus internalization process.
Many viruses enter cells with their cognate receptors by using
constitutive endocytic trafficking pathway(s); for example, Molo-
ney murine leukemia virus internalizes with murine cationic
amino acid transporter (38), Nipah virus internalizes with ephrin
B2 (17), Poliovirus internalizes with CD155 (16), and some coro-
naviruses endocytosewith theirmajor receptor aminopeptidaseN
(24). Some viruses have been reported to stimulate receptor traf-
ficking and endocytosis: severe acute respiratory syndrome coro-
navirus triggers angiotensin converting enzyme 2 endocytosis
(70) and herpes simplex virus induces nectin-1/virus complex in-
ternalization (63). At present, limited information is available on
the role of receptor trafficking in HCV entry and whether virus
engagement promotes receptor endocytosis. In the present study
we demonstrate that anti-CD81 monoclonal antibodies (MAbs)
can inhibit HCV infection at late times after virus internalization,
suggesting an intracellular site of antibody neutralization and a
role for endosomalCD81 in virus infection. Ligation ofCD81with
antibodies or HCV particles promotes receptor endocytosis in a
clathrin- and dynamin-dependent process. Live cell imaging dem-
onstrates antibody-primed CD81 and claudin-1 coendocytosis
and fusion with Rab5 expressing early endosomes, supporting a
role for this receptor complex in virus internalization and fusion
with endosomal membranes.
MATERIALS AND METHODS
Cell lines, antibodies, and reagents. Huh-7.5 cells (Charles Rice, The
Rockefeller University, New York, NY) (9), Huh-7 Lunet cells (Thomas
Pietschmann; Twincore, Hanover, Germany) (7), and 293T cells (Amer-
ican Type Culture Collection) were propagated in Dulbecco modified
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Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS)–1% nonessential amino acids (Invitrogen, California) and grown
in a humidified atmosphere at 37°C in 5%CO2. Huh-7.5 cells were trans-
duced to express AcGFP.CD81, as previously reported (26). Huh-7 Lunet
cells were transduced to express wild-type CD81 and a CD81 mutant
lacking the C-terminal cytoplasmic domain (CD81C) (6) (a gift from
Martin Hemler, Harvard, Cambridge, MA). Claudin-1 expression in
Huh-7.5 cells was siRNA silenced (Dharmacon) using Lipofectamine
RNAiMAX according to the manufacturer’s instructions.
Anti-CD81 MAbs 2s66 and 2s131 were generated after immunization
of mice with recombinant full-length CD81 (32). Purified mouse immu-
noglobulin was a gift fromM.Goodall (University of Birmingham). Anti-
CD81 JS81 (BD Biosciences) and 1.3.3.22 (Santa Cruz) MAbs were
purchased from their respective suppliers. Anti-CD81 affinity for recom-
binant MBP-CD81 large extracellular loop (LEL) (19) was assessed using
the Biacore 3000 system (Biacore AB). RecombinantMBP-CD81 was im-
mobilized to a CM5 chip using a standard amine coupling method (Bia-
core, GE Healthcare) and increasing concentrations of anti-CD81 MAbs
flowed over the chip surface (3.9 to 500 M) at 5 l/min at 25°C for 50
min and dissociation recorded for 60 min. To control for nonspecific
protein interactions, all MAbs were flowed over an “empty” channel. The
binding affinity (Kd) for each MAb was quantified by fitting a one-site
binding (hyperbola) curve to the data. Anti-claudin-1 clone 421203 was
purchased from R&D Systems. Anti-EEA1 clone1G11 was obtained from
Abcam. Anti-tubulin clone T9026 was purchased from Sigma. Alexa-594
conjugated transferrin (Tfn-594) and secondary Alexa 488/594-labeled
goat anti-mouse, goat anti-rabbit, and goat anti-rat immunoglobulins
were obtained from Invitrogen. Species-specific secondary antibodies
were used to detect the colocalization of anti-receptor antibodies, and
their specificities were confirmed in each staining experiment.
Virus genesis, infection, and anti-CD81neutralization.Cell culture-
derivedHCV (HCVcc) J6/JFHwas generated as previously described (40).
Briefly, RNAwas transcribed in vitro from full-length genomes (RiboMax
t7 kit; Promega) and electroporated into Huh-7.5 cells. Viral stocks were
generated by two sequential passages throughHuh-7.5 cells with a specific
infectivity in the range of 1/500 to 1/780 (21). Supernatantswere collected,
pooled, and stored at 80°C. Infected cells were detected by methanol
fixation and staining forHCV-encodedNS5AwithMAb 9E10 (a gift from
Charles Rice and Tim Tellinghuisen Rockefeller University); bound anti-
body was detected with anti-mouse IgG-Alexa 488 and quantified by enu-
merating NS5A-expressing cells.
Huh-7.5 cells were seeded at 1.5 104 cells/cm2, and the following day
the medium was replaced with ice-cold 3% FBS-DMEM containing J6/
JFH, followed by incubation on ice for 30 min. The cells were washed, the
medium was replaced with prewarmed 3% FBS-DMEM and, at 0, 20, 60,
and 120 min, anti-CD81 MAbs, at a concentration known to neutralize
95% virus infectivity (5 g/ml) or proteinase K (PK; 50 g/ml) were
added in serum-free DMEM. PK-treated cells were subsequently incu-
bated with 3% FBS-DMEM to inactivate its activity, as previously re-
ported (59). At 48 h postinfection, the cells were fixed, and the infectivity
was quantified (59). Virus escape from anti-CD81 or PK was calculated
relative to themaximumneutralization at 120min, and the time taken for
50% of the virus (t1/2) to escape treatments was determined.
Pseudoviruses expressing a luciferase reporter were generated as pre-
viously described (30). Briefly, 293T cells were transfected with a 1:1 ratio
of plasmids encoding HIV provirus expressing luciferase and HCV strain
H77 E1E2 envelope glycoproteins (HCVpp), murine leukemia virus en-
velope glycoprotein (MLVpp), vesicular stomatitis virus G glycoprotein
(VSV-Gpp), or empty vector (Envpp). Supernatants were harvested 48 h
posttransfection and filtered, and virion-associated p24 was determined
using a commercial assay (Aalto Bioreagents). Infection was quantified by
measuring the luciferase activity (relative lights units [RLU]), and the
specific infectivitywas determined by subtracting themeanEnvpp signal
from the HCVpp, MLVpp, or VSV-Gpp values.
Cell surface biotinylation endocytosis assay. Huh-7.5 cells were
seeded at 1.5 104 cells/cm2 and the following day serum starved for 60
min and, where indicated, incubated with Dynasore (80 M) for 30 min,
prior to adding Sulfo-NHS-SS-biotin (Pierce) at 0.5 mg/ml for 30 min at
4°C. The cells were washed and maintained at 4°C or transferred to 37°C
for 60 min in the presence or absence of antibodies or viral pseudopar-
ticles, as indicated. After the cells were returned to 4°C, they were washed
with ice-cold buffer (50 mM Tris [pH 7.5], 100 mM NaCl [pH 8.6]) and
biotin cleaved from surface-labeled proteins by incubation with the cell-
impermeable reducing agent 2-mercaptoethanesulfonic acid at 15 mg/ml
(MesNA; Sigma) for 30 min or incubation with ice-cold buffer in the
absence of MesNA to determine the total protein expressed at the cell
surface. The cells were lysed in lysis buffer (1% Brij97, 10 mM Tris [pH
7.5], 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% sodium azide).
Biotinylated proteins were immunoprecipitated from defined quantities
of cell lysate with streptavidin-coupled Dynabeads (Invitrogen). Precipi-
tates and whole-cell lysates were separated by SDS-PAGE, transferred
onto polyvinylidene difluoride membrane, and probed for CD81, clau-
din-1, or tubulin expression by enhanced chemiluminescence (Gene-
Flow). Densitometric analysis was performed using ImageJ software and
the percentage of internalized CD81 or claudin-1 presented relative to the
total CD81 or claudin-1 expressed at the cell surface.
Quantitative imaging of CD81 and claudin-1 endocytosis. Parental
Huh-7.5 cells or those transduced to express AcGFP.CD81were seeded on
glass coverslips at 1.5  104 cells/cm2 and the following day incubated
with anti-CD81 or anti-claudin-1MAbs in 3%FBS-DMEM–0.5%bovine
serum albumin (BSA) at 37°C. The cells were fixed in 3.6% electron mi-
croscope-grade formaldehyde (EM-F; TAAB,UnitedKingdom), and pro-
tein-antibody complexes were detected using Alexa Fluor-conjugated an-
tibody diluted in phosphate-buffered saline–0.05% saponin–0.5% BSA
for 60min at room temperature. The cells were counterstainedwithDAPI
(4=,6=-diamidino-2-phenylindole; Invitrogen) for 5 min, and coverslips
weremounted onto glass slides (ProLongGold Antifade; Invitrogen). The
cells were imaged by laser scanning confocal microscopy (LSCM; Zeiss
LSM510) using a100 oil immersion objective lens. To avoid any bias in
the selection of cells for quantitation, the cells were initially identified by
their DAPI nuclear stain and imaged for CD81 or claudin-1 expression.
Microscope settings were optimized for each fluorescent protein to obtain
the highest signal to noise ratio while controlling for cross talk. z-sections
were collected, and the central section found to give optimal resolution.
Consequently, a single 1-m z-section across the cell center were selected
for quantitation. CD81 and claudin-1 localization at the plasma mem-
brane and intracellular locations were quantified by using the overlay and
intensity frequency tools included with the Zeiss LSCM software. Cellular
protein expression (arbitrary fluorescence units [AFU]) was calculated by
combining the number of fluorescent pixels andmultiplying this value by
the average intensity. The fluorescence intensity at the plasma membrane
and the intracellular locations were determined by extracting the regions
of interest from the whole-cell image. The results are expressed as a per-
centage of the total fluorescence and represent the mean intracellular
fluorescence intensity the standard error of themean (SEM) of between
10 and 20 cells. Statistical analyses were performed using nonparametric
one-way analysis of variance (ANOVA; Kruskal-Wallis test) or the Stu-
dent t test in Prism 4.0, where necessary corrections for multiple compar-
isons were made. Intracellular colocalization was determined using Im-
ageJ colocalization finder plug-in software, and the overlap coefficient is
presented as a percentage of the colocalized pixels averaged from analyz-
ing 10 cells.
MechanismofCD81 endocytosis.Huh-7.5 cellswere transfectedwith
green fluorescent protein (GFP) control plasmid or GFP-tagged trans-
dominant mutants of Eps15 (GFP-EH29; Alexandre Benmerah, Institute
Cochin, Paris, France) and Dynamin2 (K44A-GFP; Mark Niven, The
Mayo Clinic, Rochester, MN) using Lipofectamine 2000 according to the
manufacturer’s instructions (Invitrogen). GFP-, GFP-EH29-, and K44A-
GFP-expressing cells were seeded onto glass coverslips at 1.5 104 cells/
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cm2 and incubated in serum-free medium for 60 min at 37°C; where
indicated, naive Huh-7.5 cells were preincubated with Dynasore (80M)
or dimethyl sulfoxide (DMSO) control for 60 min at 37°C, followed by
anti-CD81 or Tfn-594 in the continued presence or absence of Dynasore
for the indicated time intervals. To assess the role of Rho GTPases and
epidermal growth factor (EGF) in CD81 endocytosis, Huh-7.5 cells were
serum starved overnight and then incubated with C3 transferase (Cyto-
skeleton) at 5g/ml for 16 h, Rac-1 inhibitor (Calbiochem) at 100Mfor
60 min, EGF at 1 g/ml, or Erlotinib at 10 M in serum-free medium for
60min, respectively, prior to adding anti-CD81 2s66 at 2g/ml for 60min
at 37°C. The cells were immediately fixed with EM-F and CD81, visual-
ized, and quantified as detailed above.
Live cell imaging of CD81 and claudin-1 trafficking. Parental Huh-
7.5 and those transfected to express GFP-Rab5 (Alexandre Benmerah)
were seeded in glass-bottom culture dishes at 1.5  104 cells/cm2. The
following day, the cells were incubated for 30 min at 37°C with fluores-
cence-labeled anti-CD81 2s66 and anti-claudin-1 labeled with the ATTO
fluorophores 647N and 565, respectively (ATTO-TEC, Seigen, Germany).
The cells were washed and placed in phenol red-free 3% FBS-DMEM
supplemented with 20 mMHEPES. Real-time LSCM was performed (in-
verted Zeiss 780) of a 1-m z-section through the center of the cell using
a 100 oil immersion objective lens at 37°C over 5 min, and the images
were processed using Zeiss software.
HCV-induced receptor endocytosis.Huh-7.5 cells expressing AcG-
FP.CD81 were seeded at 1.5  104/cm2 on glass coverslips and incu-
bated the following day with lentiviral pseudoparticles or HCVcc J6/
JFH for 1 h at 37°C at an approximate multiplicity of infection of 0.3.
J6/JFH was incubated with 100 g of anti-HCV IgG or control IgG/ml
for 1 h at 37°C or at 65°C for 1 h, prior to inoculating the cells. The cells
were fixed in EM-F using MAbs, intracellular CD81/claudin-1 imaged,
and quantified as described above. In parallel plates, unbound J6/JFH
was removed by washing, and the medium was replenished with 3%
FBS-DMEM for 48 h, after which the virus infection was quantified by
enumerating NS5A-expressing cells.
RESULTS
Anti-CD81MAbs neutralizeHCV infection after virus internal-
ization. Several reports have studied the time for HCV to escape
the neutralizing activity of anti-receptor antibodies to investigate
the temporal involvement of cellular molecules in the virus entry
process (13, 21, 23, 37, 75). Themajority of these reports have used
the commercially available anti-CD81 MAbs JS81 and 1.3.3.22
that bind conformation-dependent epitopes in the large extracel-
lular loop (LEL) (29). We recently generated two MAbs 2s66 and
2s131 that recognize a linear epitope in CD81 (amino acids 173 to
192) and demonstrate a significantly higher affinity for CD81 LEL
than JS81 or 1.3.3.22 (2s66, Kd 3.33 M; 2s131, Kd 2.09 M;
JS81, Kd 31.69 M; and 1.3.3.22, Kd 76.2 M) (Fig. 1A). To
ascertain whether the affinity or epitope specificity of CD81MAbs
plays a role in their mode of neutralization, we compared the time
for HCV to escape the neutralizing activity of theseMAbs. HCVcc
J6/JFH was bound to Huh-7.5 cells on ice for 30 min, unbound
virus removed by washing and entry initiated by transferring the
cells to 37°C. Anti-CD81MAbswere added at a concentration that
inhibited95% of virus infectivity at the indicated times, and the
half-time (t1/2) for HCV to escape their neutralizing activity was
assessed (Fig. 1B).HCV J6/JFH escaped the neutralizing activity of
2s66 and 2s131 at significantly later times (52 and 60 min, respec-
tively) thanMAbs JS81 and 1.3.3.22 at 36 and 37min, respectively
(Fig. 1C). To independently assess HCV internalization, we mea-
sured the time for HCV to escape the proteolytic activity of the
serine protease, PK. J6/JFH acquired resistance to PK after only 18
min (t1/2) (Fig. 1C), a finding consistent with our earlier report
(59). The observation that anti-CD81MAbs could neutralize virus
infection up to 60 min after internalization is initiated and long
FIG 1 Anti-CD81 MAbs neutralize HCV postinternalization. (A) Anti-CD81 binding affinity for MBP-CD81 was assessed by surface plasmon resonance. The
data are representative of two independent experiments. (B) Schematic illustration of experimental design. (C) Time course of J6/JFH escape from proteinase K
(PK), JS81, and 2s131. The time for J6/JFH to escape 50% of the neutralizing effects of PK and anti-CD81 MAbs (t1/2) was calculated relative to the maximum
inhibition observed at 120 min and is presented in the accompanying table. The data presented are from a single experiment and are representative of two
independent experiments.
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after PK has ceased to have an effect suggests intracellular sites for
anti-CD81MAb neutralization and a role for endosomal CD81 in
virus infection.
CD81 endocytosis. The majority of CD81 in Huh-7.5 hepa-
toma cells localizes to the plasmamembranewith a limited pool of
intracellular protein detected (Fig. 2A, upper panel). To study
CD81 endocytosis, Huh-7.5 cells were incubated with a saturating
concentration of anti-CD81MAbs JS81, 1.3.3.22, 2s66, or 2s131 at
37°C for 60 min. Cell surface-bound MAb was removed by a low
pH treatment, the cells were fixed and permeabilized, and intra-
cellular CD81-MAb complexes were visualized by confocal mi-
croscopy. Significantly greater amounts of intracellular 2s66 and
2s131were detected compared to JS81 and 1.3.3.22 (Fig. 2A, lower
panel), which is consistent with our earlier neutralization data
showing later escape times forMAbs 2s66 and 2s131 (Fig. 1C). To
confirm we were studying intracellular CD81, we demonstrated
that saponin permeabilization was required to visualize CD81
puncta and low pH treatment designed to remove cell surface-
bound MAb had minimal effect on secondary antibody detection
of intracellular CD81 (Fig. 2B).
To confirm that antibody ligation promoted CD81 endocyto-
sis, we surface labeledHuh-7.5 cells with Sulfo-NHS-SS-biotin on
ice according to published protocols and maintained the cells on
ice to prevent endocytosis or incubated at 37°C for 1 h in the
presence of irrelevantmouse immunoglobulin or anti-CD81 2s66.
Subsequent incubation of the cells with MesNA cleaves biotin
from surface-labeled proteins, while internalized proteins are pro-
tected. Total cell surface-labeled proteins or biotinylated proteins
that have entered the cell are detected by streptavidin capture, and
CD81 was visualized by Western blotting. Incubation with anti-
CD81 2s66 significantly stimulated CD81 endocytosis (19.5%),
whereas control IgG treated cells showed a low level of constitutive
endocytosis (6%) (Fig. 3A). Under identical conditions we failed
to precipitate the intracellular protein tubulin, confirming specific
labeling of cell surface proteins (Fig. 3B).
We noted that antibody/biotin removal from the cell surface
was on occasion incomplete. Therefore, to further study the
mechanism of CD81 internalization, we developed an imaging-
based approach to quantify plasma membrane and intracellular
CD81, allowing the use of fluorescently tagged transdominant-
negative proteins/antibodies. Initial experiments demonstrated
that a 1-h treatment with MAb 2s66 increased intracellular local-
ization of AcGFP.CD81 by 16.8% (Fig. 3C). Comparable results
were obtained from analyzing 10 or 20 cells, and the data showed
a Gaussian distribution, demonstrating an adequate sampling of
the cell population (Fig. 3C).
The increased detection of intracellular CD81 observed with
MAbs 2s66 and 2s131 compared to JS81 and 1.3.3.22 (Fig. 2A)
may reflect differences in binding affinity or epitope-specific ef-
fects of MAb ligation on CD81 trafficking. The observation that
2s66 FAb boundCD81 LELwith a reducedKd of 44Mcompared
to 3.33 M for the complete IgGmolecule (Fig. 1A) allowed us to
study the role of ligand affinity on CD81 endocytosis. Both IgG
and FAb antibody preparations at equimolar concentrations in-
duced comparable levels of AcGFP.CD81 internalization (16.8
and 15.8%, respectively) (Fig. 3C), demonstrating that bivalent
antibody induced cross-linking is not required to promote CD81
internalization, and ligand-induced CD81 internalization may
not solely be driven MAb binding affinity. Brazzoli et al. reported
that antibody ligation of CD81 promoted protein movement to
cell-cell contacts inHuh-7 cells, suggesting amechanism forCD81
tethered virus to interact with tight-junction-associated claudin-1
and occludin proteins (11). In contrast, we found CD81 to pref-
erentially localize at cell-cell contacts in naive untreated cells (Fig.
2A) and failed to observe any significant effect of MAb engage-
ment on CD81 localization at cell-cell contacts (Fig. 3D).
Mechanism of CD81 internalization.HCV has been reported
to enter cells in a clathrin-dependentmanner (8, 48). To assess the
clathrin dependency of CD81 endocytosis, we transfected Huh-
7.5 cells to express GFP or GFP-tagged transdominant mutants of
Eps15 (EH29), a regulatory protein essential for the formation of
clathrin-coated pits (4), orDynamin2 (K44A), a protein necessary
for the scission of vesicles from the plasma membrane (46) (re-
viewed in reference 57). Both mutants reduced Alexa 594-labeled
transferrin uptake (Fig. 4A), confirming clathrin-dependent en-
docytosis. CD81 internalizationwas reduced by 51.5 and 59.5% in
GFP-EH29- and K44A-GFP-expressing cells, respectively, com-
pared to control GFP-transfected cells (Fig. 4A), demonstrating a
clathrin- and dynamin-dependent internalization process. In
agreement with these data, treating Huh-7.5 cells with the dy-
namin inhibitor Dynasore (34, 44, 50, 65) reduced both transfer-
rin and CD81 uptake (Fig. 4B). Decreased CD81 endocytosis in
the presence of Dynasore was confirmed by surface biotinylation
(Fig. 4C). Furthermore, Dynasore reduced HCVcc, HCVpp, and
FIG 2 CD81 internalization. (A) The total (fixed and permeabilized [upper
panel]) or internalized (live cell staining [lower panel]) CD81 in Huh-7.5 cells
was evaluated with the anti-CD81 MAbs JS81, 1.3.3.22, 2s66, or 2s131 at 2
g/ml for 60 min. To observe the internalized CD81 after live cell staining,
surface-bound MAb was removed by low-pH treatment, and the cells were
fixed and permeabilized with EM-formaldehyde and saponin, respectively.
The average intracellular fluorescence intensity (arbitrary fluorescence unit
[AFU]) per cell was calculated from 10 cells. (B) Cell surface-expressed CD81
was visualized by staining live Huh-7.5 cells with anti-CD81 MAb 2s131 (2
g/ml) for 1 h at 37°C and fixed, and bound antibody was detected with
anti-mouse immunoglobulin Alexa 488. Total CD81 representing the cell sur-
face and intracellular pools was detected by permeabilizing the cells with
0.05% saponin postfixation. Low-pH treatment of antibody-treated Huh-7.5
cells removed the cell surface-bound MAb and enabled the sole detection of
intracellular antibody after the fixation and permeabilization of cells. Nuclei
were stained with DAPI, and single 1-mz-sections from the central region of
the cell were obtained by laser scanning confocal microscopy.
Farquhar et al.
4308 jvi.asm.org Journal of Virology
VSV-Gpp infection (33) but had minimal effect(s) on MLVpp
infection (38) (Fig. 4D).We conclude that CD81 internalizes via a
clathrin- and dynamin-dependent process.
CD81 endocytosis is independent of the intracellular C-ter-
minal domain. Cell surface receptor endocytosis is often regu-
lated by motifs within the cytoplasmic tail that bind adaptor pro-
teins involved in the formation of clathrin coated pits or caveolae
(39). The tetraspanins CD63, CD151, and CD82 have been re-
ported to internalize by diverse cellular routes (41, 56, 71) via an
endocytic motif YXXØ in their C-terminal domains (10, 27).
However, CD81 does not contain this endocytic motif. To deter-
mine whether the C-terminal cytoplasmic domain is required for
CD81 endocytosis, amutant protein lacking this region (CD81C)
was expressed in Huh-7 Lunet cells that express low levels of en-
dogenous CD81 detectable by flow cytometry (Fig. 5A). We con-
firmed cell surface expression of exogenous wild-type and
CD81C proteins and observed comparable levels of internalized
CD81 after 2s66MAb treatment (Fig. 5A and B), suggesting a role
for partner proteins to regulate CD81 endocytosis. The GTPases
Rho and Rac-1 were reported to play a role in HCV entry (11);
however, their mode of action was not defined. To study their
involvement in CD81 endocytosis, Huh-7.5 cells were incubated
with inhibitors of Rho (C3 transferase) or Rac-1. Inhibition of
Rho significantly reduced antibody stimulated CD81 endocytosis
compared to control cells (Fig. 5C), whereas Rac1 inhibition had
no observable effect, supporting a role for Rho GTPase in CD81
endocytosis. Both inhibitors reduced HCVpp infection as previ-
ously published (11).
EGF receptor (EGF-R) was recently reported to play a role in
HCV entry by promoting particle internalization (43). Reports
that EGF-Rs associate with the tetraspanins CD9, CD81, and
CD82 (51) and that EGF promotes CD82 endocytosis (71)
prompted us to investigate the effects of EGF-R activation on
CD81 endocytosis. We confirmed the stimulatory and inhibitory
effect of EGF andErlotinib, respectively, onHCVpp entry inHuh-
7.5 cells (data not shown). However, treating cells with EGF or
receptor kinase inhibitor Erlotinib had no effect on CD81 endo-
cytosis (Fig. 5D), demonstrating that EGF-R does not promote
HCV entry by regulating CD81 endocytosis.
CD81 and claudin-1 coendocytosis. We (26) and others (73)
FIG 3 Quantification of CD81 internalization. CD81 endocytosis was examined by surface biotinylation. Total surface-biotinylated protein (lane 1), biotin-
labeled protein internalized at 4°C (lane 2), or biotin-labeled protein internalized at 37°C for 1 h in the presence of irrelevant mouse immunoglobulin (lane 3)
or anti-CD81 2s66 (lane 4) (2 g/ml) was captured by streptavidin pulldown. Precipitates (P, upper panel) and whole-cell lysates (WCL, lower panel) were
subjected to SDS-PAGE, and the reactivity with anti-CD81 (A) or anti-tubulin (B) was assessed byWestern blotting. The data are representative of two separate
experiments from which the intracellular CD81 relative to total surface biotinylated CD81, determined by densitometric analysis, is combined. The data were
compared using a Student t test (, P 0.01). (C) Huh-7.5 cells expressing AcGFP.CD81 were incubated with control mouse immunoglobulin or equimolar
amounts of 2s66 or Fab for 1 h at 37°C. After fixation, 10 or 20 cells were imaged, and the intracellular CD81 fluorescence was quantified as a percentage of the
total fluorescence the SEM. The data were compared by using a nonparametric ANOVA (Dunn’s test, Kruskal-Wallis, ANOVA [***, P 0.001]) and revealed
no significant differences between 10 and 20 data points. (D) Huh-7.5 cells were incubated with anti-CD81 MAb 2s131 (2 g/ml) for 10 or 60 min at 37°C and
then fixed and permeabilized with saponin (0.05%); surface and intracellular bound MAb was visualized with anti-mouse immunoglobulin-Alexa 488. Similar
observations were made with anti-CD81 MAb 2s66.
Role of CD81 and Claudin-1 in HCV Entry
April 2012 Volume 86 Number 8 jvi.asm.org 4309
previously reported that CD81 associates with claudin-1 and the
receptor complex plays a role in HCV entry (25). Tight-junction
proteins such as claudin-1 are known to readily endocytose via
stimulus-specific endocytic pathways (67, 74). To ascertain
whether CD81 and claudin-1 coendocytose, Huh-7.5 cells were
incubated with anti-CD81 and anti-claudin-1 MAbs, surface-
bound antibody was removed by a low pH treatment, and the cells
were fixed and permeabilized prior to the addition of a secondary
antibody. We observed that 46% of the intracellular CD81 colo-
calized with claudin-1 internalized from the plasma membrane
(Fig. 6A). Similarly, incubating Huh-7.5 cells with anti-CD81
MAb alone, followed by low pH and permeabilization steps and
anti-claudin-1 staining, demonstrated intracellular vesicular
costaining for CD81 and claudin-1 (Fig. 6A), suggesting the coen-
docytosis of both receptormolecules. To confirmCD81/claudin-1
coendocytosis, Huh-7.5 cells were incubated with directly labeled
fluorescent anti-CD81 2s66*647N and anti-claudin-1*565 MAbs
at 37°C for 30 min, unbound MAbs were removed by washing,
and the cells were imaged over a 5-min time period. We observed
CD81 and claudin-1 trafficking at the plasma membrane prior to
their coendocytosis (Fig. 6B) (see Movie S1 in the supplemental
material). HCV-cell fusion is reported to occur within early endo-
somes (48, 53). To study the localization of internalizedCD81 and
claudin-1, Huh-7.5 cells were transfected with a GFP-tagged early
endosomal marker Rab5 (GFP-Rab5), and recently internalized
CD81 and claudin-1 proteins were visualized with fluorescence-
labeled antibodies. Real-time imaging showed CD81- and clau-
din-1-containing vesicles trafficking to and colocalizing with
Rab5 expressing early endosomes (Fig. 6C) (see Movie S2 in the
supplemental material), demonstrating the recruitment of both
receptors to early endosomes. Costaining GFP-Rab5 expressing
vesicles with anti-EEA1 confirmed correct targeting of GFP-Rab5
FIG4 CD81 internalization is clathrin and dynamin dependent. (A)Huh-7.5 cells expressingGFP-control, GFP-EH29, or K44A-GFPwere incubatedwithAlexa
594-labeled transferrin (Tfn-594) or anti-CD81 2s131 (2 g/ml) for 1 h at 37°C. Intracellular transferrin and CD81-Ab fluorescence in 10 selected GFP-EH29-
and K44A-GFP-expressing cells was measured and is presented relative to the intracellular fluorescence in control GFP-expressing cells. (B) Serum-starved
Huh-7.5 cells were treated with Dynasore (80 M) or DMSO prior to incubation with Tfn-594 or 2s131 for 1 h at 37°C. After fixation, bound antibody was
visualized using anti-mouse immunoglobulin-Alexa 488; the intracellular transferrin andCD81-Abfluorescence in a sample population of 10 individual cells was
determined and is presented relative to the intracellular fluorescence in control untreated cells. (C) Biotin-labeled proteins internalized after incubation of the
cells at 4°C (lane 1) or 37°C for 1 h in the presence of 2g of anti-CD81 2s66/ml after pretreatment withDMSO control (lane 2) or 80MDynasore (lane 3) were
captured by streptavidin pulldown. Precipitates (P, upper panel) andwhole-cell lysates (WCL, lower panel) were subjected to SDS-PAGE, and the reactivity with
anti-CD81 was assessed by Western blotting. The data are representative of two separate experiments from which the relative changes, as determined by
densitometric analysis, are combined. The data were compared using a Student t test (***, P 0.001). (D) Huh-7.5 cells were serum starved and incubated with
Dynasore prior to infectionwithHCVcc J6/JFH,HCVpp-H77,MLVpp, or VSV-Gpp. Infectivity is expressed relative to untreated control cells and represents the
mean of three replicate infections. The data presented are from a single experiment and are representative of three independent experiments. Transferrin and
CD81 internalization relative to control was compared using a nonparametric ANOVA (Dunn’s test, Kruskal-Wallis, ANOVA [*, P 0.05; **, P 0.01; ***, P
0.001)].
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to early endosomes (Fig. 6D). To ascertain whether claudin-1 ex-
pression is essential for CD81 endocytosis, we siRNA silenced
claudin-1 expression and monitored the effects of MAb 2s66 on
CD81 endocytosis. There was no difference in anti-CD81 stimu-
lated endocytosis in claudin-1 silenced cells (Fig. 6E), suggesting
CD81 endocytosis is not regulated by claudin-1 expression per se.
HCV promotes CD81 and claudin-1 endocytosis. To investi-
gate whether HCV can promote CD81 and claudin-1 endocytosis,
Huh-7.5 cells were incubated with cell culture-grown HCV parti-
cles (HCVcc), and AcGFP.CD81 and claudin-1 internalization
was compared to that in mock-infected (control) cells (Fig. 7A).
HCVcc promoted a significant increase in intracellular CD81
(21.4%) and claudin-1 (15.2%), resulting in pixel saturation that
may underestimate CD81 endocytosis. Heat inactivation or anti-
HCV immunoglobulin inhibited HCVcc infectivity (Fig. 7B) and
ablated the effect(s) of virus on CD81 and claudin-1 internaliza-
tion, suggesting that infectious virus is required to initiate recep-
tor endocytosis. We confirmed HCVcc stimulation of endoge-
nous CD81 endocytosis by antibody detection (Fig. 7C). After
HCVcc treatment we observed 89%of intracellular CD81 colocal-
izing with claudin-1 internalized from the plasma membrane
(Fig. 7D).
To confirm that this effect was mediated via the virus-encoded
glycoproteins, we studied the effect of recombinant soluble HCV
E2 glycoprotein (sE2) or lentiviral pseudoparticles expressing
HCV E1E2 glycoproteins (HCVpp) or envelope-deficient parti-
cles (Envpp) on AcGFP.CD81 internalization in Huh-7.5 cells.
Both sE2 and HCVpp induced a significant increase, 15.6 and
27.8%, respectively, in intracellular AcGFP.CD81 compared to
Envpp-treated cells (Fig. 8A and B). Furthermore, we confirmed
HCVpp stimulation of CD81 (30.9%) and claudin-1 (27.4%) en-
docytosis by surface biotinylation (Fig. 8C). In conclusion, these
data illustrate HCV envelope glycoprotein stimulated CD81 and
claudin-1 endocytosis.
FIG 5 C-terminal-independent and Rho GTPase-dependent CD81 endocytosis. (A) Parental and Huh-7 Lunet cells transduced to express wild-type (wt) CD81
or a mutant lacking the C-terminal tail (CD81C) were stained for cell surface CD81 expression in the presence of 0.01% sodium azide with anti-CD81 2s131 (2
g/ml) (black line) or isotype control (solid gray) and then analyzed by flow cytometry. (B) Huh-7 Lunet cells expressing wt or CD81C were incubated with
anti-CD81 MAb 2s131 (2 g/ml) for 1 h at 37°C, fixed, and permeabilized, and the bound antibody was visualized. Representative images are shown, and
intracellular antibody fluorescence is presented as a percentage of the total fluorescence the SEM in a sample population of 20 cells, where each circle represents
an individual cell. (C)Huh-7.5 cells were incubatedwith C3 transferase (5g/ml, 16 h) or Rac-1 inhibitor (100M, 1 h), followed by anti-CD81 2s131 (2g/ml)
for 1 h at 37°C. The cells were fixed, and antibodywas visualized as described in the text. Intracellular antibody fluorescence of 20 cells is presented as a percentage
of the total fluorescence the SEM, where each circle represents an individual cell. CD81 internalization in the presence of C3 transferase or Rac-1 inhibitor
relative to control was compared using a nonparametric ANOVA (Dunn’s test, Kruskal-Wallis, ANOVA [***, P 0.001]). (D)Huh-7.5 cells were serum starved
overnight and incubated with EGF or Erlotinib for 1 h at 37°C prior to incubation with anti-CD81 2s66 (2 g/ml) for 1 h at 37°C. The cells were fixed and
permeabilized, and antibodies were visualized as described in the text. The intracellular antibody fluorescence of 10 cells is presented as a percentage of the total
fluorescence  the SEM, where each circle represents an individual cell. The images shown are from a single experiment and are representative of two
independent experiments.
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DISCUSSION
HCV entry is a multistep process, and there is a limited under-
standing of the role individual receptors play in virus internaliza-
tion. We demonstrate that CD81 endocytosis occurs via a clath-
rin- and dynamin-dependent process in association with
claudin-1. Importantly, HCV promotes CD81 and claudin-1 en-
docytosis, in a manner specifically inhibited by neutralizing anti-
HCV immunoglobulin, supporting a direct role for these recep-
tors in virus internalization. Our observation that anti-CD81
MAbs neutralize HCV infection after virus internalization is con-
sistent with an intracellular site of antibody neutralization and a
role for CD81 in trafficking virus to the endosomes for subsequent
fusion events.
Brazzoli et al. reported that anti-CD81 MAb JS81 induced a
lateral movement to cell-cell contact areas in Huh-7 hepatoma
cells in a Rho-dependent manner (11). These authors interpreted
cell-cell contacts to represent tight junctions and suggested that
HCV engagement of CD81would prime themovement of virus to
tight-junction-associated entry factors claudin-1 and occludin in
amanner similar to that of coxsackie B virus engagement of decay
accelerating factor (5). We did not observe any evidence for anti-
body or virus promoting CD81 trafficking to cell-cell contacts;
however, we confirmed that CD81 endocytosis was Rho depen-
dent. Our data showed an enrichment of CD81 at hepatoma cell-
cell contacts in untreated cells, as reported for other tetraspanin
proteins (72). In agreement with our data, Coller et al. reported
HCV endocytosis at diverse sites along the plasma membrane of
Huh-7 hepatoma cells (15). Recent reports using high-resolution
FIG 6 CD81 and claudin-1 endocytosis. (A) Huh-7.5 cells were incubated with anti-CD81 2s131 (2 g/ml) and anti-claudin-1 (2 g/ml) (upper panel) or with
anti-CD81 alone (lower panel) for 1 h, followed by a 5-min low-pH step to remove cell surface-bound MAbs prior to fixation. Intracellular anti-CD81 and
anti-claudin-1 MAbs were detected with isotype-specific anti-mouse immunoglobulin-Alexa Fluor conjugates (upper panel). For anti-CD81-treated cells, after
fixation and permeabilization, the intracellular claudin-1 was detected, and both primary antibodies were visualized with isotype-specific anti-mouse immuno-
globulin-Alexa Fluor conjugates (lower panel). Images are derived from a single experiment representative of three independent experiments. Huh-7.5 cells (B)
or Huh-7.5 cells expressing GFP-Rab5 (C) were incubated with anti-CD81 2s66 and anti-claudin-1 tagged with ATTO 647N and ATTO 565, respectively, for 30
min at 37°C. The cells werewashed, and real-time confocal imaging of a 1-mz-section through the center of the cell was performed over a period of 5min. Static
images taken from Movies S3 and S4 in the supplemental material are shown and were derived from a single experiment that is representative of three
independent experiments. (D) Huh-7.5 cells transfected to express GFP-Rab5 were fixed and stained with anti-EEA1. (E) Claudin-1 was siRNA silenced in
Huh-7.5 cells (see Materials and Methods), and protein expression was confirmed by staining control (irr) or silenced (kd) cells. CD81 endocytosis was
determined in cells incubated with anti-CD81 2s66 (2 g/ml) for 1 h at 37°C. Representative images are shown, and the intracellular antibody fluorescence is
presented as a percentage of the total fluorescence the SEM in a sample population of 20 cells, where each circle represents an individual cell.
Farquhar et al.
4312 jvi.asm.org Journal of Virology
single-particle tracking demonstrated the dynamic movement of
tetraspanins in live cells (36); using this technique we have dem-
onstrated the mobile nature of CD81 in Huh-7 cells with no evi-
dence of antibody-dependent directedmovement to cell-cell con-
tacts.
HCV entry is clathrin dependent (48), and we demonstrate
here that CD81 can endocytose via a clathrin- and dynamin-de-
pendent process. Dynamin is intrinsically linked to clathrin- and
caveolin-dependent and -independent routes of endocytosis (28).
The reported absence of Cav-1 in Huh-7 cells and the inhibitory
effect of the Eps15 transdominant mutant (14, 68) suggest a role
for dynamin in clathrin-dependent CD81 and HCV endocytosis.
Unlike tetraspanins CD63, CD151, and CD82, which have been
reported to internalize via an endocytic motif YXXØ in their C-
terminal domains (10, 27), CD81 does not contain this motif, and
a mutant protein lacking a C-terminal cytoplasmic tail can endo-
cytose and support HCV entry (6). These data suggest a role for
CD81-associating proteins in regulating its endocytosis. EGF-R
was recently reported to promote HCV entry, and we examined a
role for EGF-R in CD81 endocytosis (43, 71).We failed to observe
any effect of EGF-R activation or inhibition onCD81 endocytosis,
suggesting an alternative mechanism for EGF enhancement of
HCV infectivity. Many viruses have been shown to utilize integ-
rins during cell entry (for a review, see reference 61), integrins
associate with tetraspanins, and CD81 has been reported to di-
rectly associate with 41 (60). CD81 may utilize its association
with integrins or other known endocytic tetraspanin partner pro-
teins CD63, CD151, or CD82 to internalize. Further work is re-
quired to understand the mechanism of CD81 endocytosis in the
absence of an endocytic motif.
Silencing claudin-1 expression had no detectable effect on anti-
body-primed CD81 endocytosis, demonstrating that claudin-1 ex-
pression alone does not regulate CD81 endocytosis. Huh-7.5 cells
express low levels of receptor active claudin-6 or 9 molecules that
associate with CD81 (25) and may provide alternative partner
proteins to regulate CD81 endocytosis. Attempts to visualizeHCV
in association with CD81 or claudin-1, either at the plasmamem-
brane following binding or within intracellular vesicles using an-
FIG 7 HCV promotes CD81 and claudin-1 endocytosis. (A) Huh-7.5 cells expressing AcGFP.CD81 were mock infected (control) or incubated with HCVcc
J6/JFH, either alone or pretreated with anti-HCV Ig, control immunoglobulin, or heat inactivated at 37°C for 1 h. The cells were fixed and, where appropriate,
claudin-1 detection was performed in saponin-permeabilized cells, and the cells were then imaged as described in the text. Intracellular protein/antibody
fluorescence was quantified as a percentage of the total fluorescence  the SEM in a sample population of 10 individual cells, where each circle represents an
individual cell. The data were compared using a nonparametric ANOVA (Dunn’s test, Kruskal-Wallis, ANOVA [*, P 0.5; **, P 0.01; ***, P 0.001]). These
data are representative of two further experiments which had comparable statistical significance. (B) Infectivity of HCVcc, alone or pretreated with anti-HCV Ig,
control immunoglobulin, or heat inactivated, at 37°C for 1 h. The infectivitywasmeasured after 48 h by enumeratingNS5A-expressing cells relative to the control
and represents the mean of three replicate infections. (C) Huh-7.5 cells were incubated with HCVcc or mock infected (control) for 1 h prior to fixation and
antibody detection of CD81 in saponin-permeabilized cells. The cells were imaged as described in the text, and the intracellular antibody fluorescence was
quantified as a percentage of the total fluorescence the SEM in a sample population of 10 cells, where each circle represents an individual cell. The data were
compared using a Student t test (***, P 0.001). The data presented are from a single experiment and are representative of two independent experiments. (D)
Intracellular colocalization of AcGFP.CD81 and antibody detected claudin-1 in mock (control)- or HCVcc-treated Huh-7.5 cells at 37°C for 1 h.
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tibodies to the structural proteins, were unsuccessful, due in part
to the relatively low titer of HCV particles available for these stud-
ies. However, it is interesting that both HCVpp and HCVcc prep-
arations stimulated greater levels of CD81 and claudin-1 endocy-
tosis than saturating levels of receptor specific MAbs, suggesting
that the virus may be more effective at priming receptor endocy-
tosis.
Antiviral antibodies can neutralize infection by a variety of
mechanisms, including the blocking of virus binding to cellular
receptors or the inhibition of postentry/prefusion events within
the endosome (for reviews, see references 35 and 45). In contrast,
less is known about the mechanism and site of action of neutral-
izing anti-receptor antibodies. Anti-CD81 MAbs have been re-
ported to neutralize cell surface-boundHCV, suggesting a postat-
tachment role for CD81 in the virus internalization process. Our
current data suggest that anti-CD81 MAbs can neutralize virus at
late times, after escape from PK, proposing intracellular sites for
antibody neutralization. HCV has been reported to fuse in early
endosomes and Meertens et al. noted a time delay between HCV
internalization and endosome fusion that may reflect the recruit-
ment of other cell components or further CD81 molecules to in-
tracellular sites (48). Antibody ligation promotes CD81 internal-
ization, and we propose that treating recently infected cells with
anti-CD81 enables the subsequent fusion of internalized antibody
and HCV-containing endocytic vesicles, allowing intracellular
sites for antibody neutralization. Thus, the internalization of anti-
receptor antibodies and their fusion with vesicular virus-receptor
complexes is qualitatively different from previous reports on the
intracellular targeting of infection by virus-specific antibodies to
West Nile virus, tick-borne encephalitis virus, and influenza virus
A (20, 62, 64).
Evans et al. reported a role for claudin-1 at a late step in the
HCV entry process, using a similar experimental design to that
shown in Fig. 1 with a FLAG epitope-tagged claudin-1 molecule
and high-affinity anti-FLAG antibodies, demonstrating t1/2 times
of 72 and 18 min for anti-FLAG and anti-CD81 antibodies, re-
spectively (21). In contrast, a recent report by Krieger and co-
workers demonstrated comparable times for HCV to escape anti-
claudin-1; these studies most likely reflect the epitope specificity
and affinity of the anti-receptor antibodies under evaluation, the
different viral strains, and a hepatoma cell density that alters the
HCV internalization rate(s) (37, 59). Our study shows variation in
the time forHCV to escape differentMAbs targeting CD81, which
may be explained by differences in antibody affinity or epitope
recognition, although in our study the t1/2 for JS81 was compara-
ble to that reported by Krieger et al. (37). Importantly, we high-
light here the complexities inherent in this experimental design
and its inadequacies for studying the chronology of receptor usage
in HCV entry.
Early endosomes are points of convergence for internalized
molecules (22), where endocytosed material can acquire other
cellular or signaling components by fusing with endocytic vesicles
(31, 69). The localization of CD81/claudin-1 in Rab5-positive
early endosomes and the reported 20-min delay between HCV
internalization and fusion (48) suggests thatHCV/CD81/claudin-
1-containing vesicles may converge with other intracellular or en-
docytosed molecules prior to the fusion of virus and endosomal
membranes. Our data support a model wherein HCV infects
hepatocytes by priming CD81/claudin-1 endocytosis and exploits
the dynamic intracellular trafficking of receptor proteins.
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